好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study
Neuro-oncology
S30 - Brain Cancer: From Epidemiology to Quality of Life (4:47 PM-4:58 PM)
008

We evaluated the use of the Macarthur Competence Assessment Tool for Treatment (MacCAT-T) to assess decision-making ability in glioma patients.

Despite the identified need for glioma patients to make difficult end-of-life decisions amongst cognitive limitations, there is no universal measurement of decision-making ability for this patient population. We sought to determine whether the MacCAT-T could identify deficits in individual decision-making domains that a gross cognitive exam or informal clinician assessment might not otherwise detect.

High-grade glioma patients were consented to an IRB-approved prospective study at three timepoints requiring treatment decisions: diagnosis, recurrence, or end of life. Patients completed the Montreal Cognitive Assessment (MoCA), and providers assessed whether patients had sufficient decision-making ability based on their neurologic exam.  The MacCAT-T – designed to assess patient decision-making domains (appreciation, reasoning, and understanding) – was administered by a research assistant. MoCA, MacCAT-T, and provider data were compared to determine if the MacCAT-T provided additional information.  To evaluate feasibility, we measured administration time and obtained qualitative patient feedback. 

11 patients (median age= 68, median KPS= 80-90) were enrolled. MacCAT-T administration took on average 18.5 minutes. 90% of patients reported “increased knowledge of their treatment options” after taking the MacCAT-T.  91% of patients were deemed by clinicians to possess sufficient decision-making ability. 7 patients yielded discordant data: 2 patients with MOCA score >26 showed qualitative impairments in reasoning on the MacCAT-T and 5 patients who scored <21 were within non-impaired ranges for three of four decision-making domains.

MacCAT-T administration was feasible and the interview process was informative to patients.  In the majority of patients, there was a discordance among MOCA, MacCAT-T, and clinician assessment data.  The MacCAT-T may help in identifying mild reasoning impairments related to patients’ initial treatment decisions and should be studied further to determine its role in clinical practice.

Authors/Disclosures
Jessica F. Occhiogrosso (University of Rochester - Wilmot Cancer Center)
PRESENTER
Ms. Occhiogrosso has nothing to disclose.
Lauryn Hemminger (Strong Memorial Hospital) Dr. Hemminger has nothing to disclose.
Joy E. Burke, MD (University of Rochester) No disclosure on file
Chinazom U. Ibegbu, MD (Roswell Park Cancer Institute) Dr. Ibegbu has nothing to disclose.
Jennifer N. Serventi, PA (University Of Rochester Medical Center) Ms. Serventi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novocure.
Nimish A. Mohile, MD, FAAN The institution of Dr. Mohile has received research support from Novocure.